227 related articles for article (PubMed ID: 27074743)
1. Prognostic impact of mutation profiling in patients with stage II and III colon cancer.
Shen Y; Han X; Wang J; Wang S; Yang H; Lu SH; Shi Y
Sci Rep; 2016 Apr; 6():24310. PubMed ID: 27074743
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
[TBL] [Abstract][Full Text] [Related]
3. High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon Cancer.
Korphaisarn K; Pongpaibul A; Roothumnong E; Pongsuktavorn K; Thamlikitkul L; Anekpuritanang T; Poungvarin N; Thongnoppakhun W; Pithukpakorn M
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2319-2326. PubMed ID: 31450901
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients.
van den Broek E; Krijgsman O; Sie D; Tijssen M; Mongera S; van de Wiel MA; Belt EJ; den Uil SH; Bril H; Stockmann HB; Ylstra B; Carvalho B; Meijer GA; Fijneman RJ
Oncotarget; 2016 Nov; 7(45):73876-73887. PubMed ID: 27729614
[TBL] [Abstract][Full Text] [Related]
5. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
6.
Zeng J; Fan W; Li J; Wu G; Wu H
Int J Gen Med; 2023; 16():4109-4120. PubMed ID: 37720173
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.
Day FL; Jorissen RN; Lipton L; Mouradov D; Sakthianandeswaren A; Christie M; Li S; Tsui C; Tie J; Desai J; Xu ZZ; Molloy P; Whitehall V; Leggett BA; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Busam D; Zhao Q; Strausberg RL; Gibbs P; Sieber OM
Clin Cancer Res; 2013 Jun; 19(12):3285-96. PubMed ID: 23633456
[TBL] [Abstract][Full Text] [Related]
8. Association of KRAS, NRAS, BRAF and PIK3CA gene mutations with clinicopathological features, prognosis and ring finger protein 215 expression in patients with colorectal cancer.
Wu JB; Li XJ; Liu H; Liu YJ; Liu XP
Biomed Rep; 2023 Dec; 19(6):104. PubMed ID: 38025833
[TBL] [Abstract][Full Text] [Related]
9. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.
Gavin PG; Colangelo LH; Fumagalli D; Tanaka N; Remillard MY; Yothers G; Kim C; Taniyama Y; Kim SI; Choi HJ; Blackmon NL; Lipchik C; Petrelli NJ; O'Connell MJ; Wolmark N; Paik S; Pogue-Geile KL
Clin Cancer Res; 2012 Dec; 18(23):6531-41. PubMed ID: 23045248
[TBL] [Abstract][Full Text] [Related]
10. Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience.
Baltruškevičienė E; Mickys U; Žvirblis T; Stulpinas R; Pipirienė Želvienė T; Aleknavičius E
Acta Med Litu; 2016; 23(1):24-34. PubMed ID: 28356789
[TBL] [Abstract][Full Text] [Related]
11. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations.
Ogura T; Kakuta M; Yatsuoka T; Nishimura Y; Sakamoto H; Yamaguchi K; Tanabe M; Tanaka Y; Akagi K
Oncol Rep; 2014 Jul; 32(1):50-6. PubMed ID: 24806883
[TBL] [Abstract][Full Text] [Related]
13. [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].
Gao J; Sun ZW; Li YY; Shen L
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):579-83. PubMed ID: 23157823
[TBL] [Abstract][Full Text] [Related]
14. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
15. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer.
Foltran L; De Maglio G; Pella N; Ermacora P; Aprile G; Masiero E; Giovannoni M; Iaiza E; Cardellino GG; Lutrino SE; Mazzer M; Giangreco M; Pisa FE; Pizzolitto S; Fasola G
Future Oncol; 2015; 11(4):629-40. PubMed ID: 25686118
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer.
Birgisson H; Edlund K; Wallin U; Påhlman L; Kultima HG; Mayrhofer M; Micke P; Isaksson A; Botling J; Glimelius B; Sundström M
BMC Cancer; 2015 Mar; 15():125. PubMed ID: 25884297
[TBL] [Abstract][Full Text] [Related]
18. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
19. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer.
Manceau G; Marisa L; Boige V; Duval A; Gaub MP; Milano G; Selves J; Olschwang S; Jooste V; le Legrain M; Lecorre D; Guenot D; Etienne-Grimaldi MC; Kirzin S; Martin L; Lepage C; Bouvier AM; Laurent-Puig P
Cancer Med; 2015 Mar; 4(3):371-82. PubMed ID: 25641861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]